Literature DB >> 29339293

Methylphenidate significantly alters the functional coupling between the prefrontal cortex and dopamine neurons in the ventral tegmental area.

Ike C Dela Peña1, Guofang Shen2, Wei-Xing Shi3.   

Abstract

Amphetamine-like psychostimulants, including methylphenidate, have been shown to produce two opposing effects on dopamine (DA) neurons: a DA receptor-mediated feedback inhibition and a non-DA receptor-mediated excitation. To test whether the latter effect is mediated through the prefrontal cortex (PFC), we made dual-site recordings from the PFC and ventral tegmental area (VTA). Consistent with previous reports, methylphenidate inhibited VTA DA neurons. The D2 receptor antagonist raclopride completely reversed the inhibition and further increased the activity, particularly bursting, to above pre-drug baseline. This increase in DA cell activity was blocked by the α1 receptor antagonist prazosin, suggesting an effect mediated through α1 receptors. Recordings in the PFC showed that methylphenidate increased PFC UP state duration and shifted the functional coupling between the PFC and DA neurons from negative to positive. The former effect was partially reversed by not only prazosin, but also raclopride, whereas the latter was reversed only by raclopride. These results suggest that methylphenidate increases PFC cell activity through both α1 and D2 receptors. Its effect on PFC-DA cell functional coupling, however, is mediated through D2 receptors. The finding that the latter effect was unaffected by prazosin further suggests that it does not play a significant role in the α1-mediated excitatory effect of methylphenidate on DA neurons. However, the shift in PFC-DA cell functional coupling from negative to positive may significantly alter the relative timing between DA and glutamate release from DA and PFC terminals and thus the synaptic plasticity that depends on DA-glutamate interaction.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  D2 receptors; Dopamine neurons; Functional coupling; MethylPhenidate; Prefrontal cortex

Mesh:

Substances:

Year:  2018        PMID: 29339293     DOI: 10.1016/j.neuropharm.2018.01.015

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  5 in total

1.  Methylphenidate Attenuates the Cognitive and Mood Alterations Observed in Mbnl2 Knockout Mice and Reduces Microglia Overexpression.

Authors:  Carla Ramon-Duaso; Thomas Gener; Marta Consegal; Cristina Fernández-Avilés; Juan José Gallego; Laura Castarlenas; Maurice S Swanson; Rafael de la Torre; Rafael Maldonado; M Victoria Puig; Patricia Robledo
Journal:  Cereb Cortex       Date:  2019-07-05       Impact factor: 5.357

2.  PharmGKB summary: methylphenidate pathway, pharmacokinetics/pharmacodynamics.

Authors:  Tyler Stevens; Katrin Sangkuhl; Jacob T Brown; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2019-08       Impact factor: 2.089

3.  Hypothesis: Amelioration of obesity-induced cognitive dysfunction via a lorcaserin-betahistine combination treatment.

Authors:  Ike C Dela Peña; Johnny D Figueroa; Wei-Xing Shi
Journal:  Pharmacol Res Perspect       Date:  2022-06

4.  Prior Activation of 5-HT7 Receptors Modulates the Conditioned Place Preference With Methylphenidate.

Authors:  Cristiana Carbone; Sara Lucia Maria Lo Russo; Enza Lacivita; Annika Frank; Enrico Alleva; Holger Stark; Luciano Saso; Marcello Leopoldo; Walter Adriani
Journal:  Front Behav Neurosci       Date:  2019-09-18       Impact factor: 3.558

5.  Methylphenidate affects task-switching and neural signaling in non-human primates.

Authors:  Abigail Z Rajala; Luis C Populin; Rick L Jenison
Journal:  Psychopharmacology (Berl)       Date:  2020-02-18       Impact factor: 4.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.